Stockscreener 앱 받기
3.36
9.45%
0.29
시간 외 거래:
3.50
0.14
+4.17%
전일 마감가:
$3.07
열려 있는:
$3.3
하루 거래량:
700.39K
Relative Volume:
4.63
시가총액:
$58.92M
수익:
-
순이익/손실:
$-24.05M
주가수익비율:
-1.5628
EPS:
-2.15
순현금흐름:
$-17.78M
1주 성능:
+6.67%
1개월 성능:
+10.16%
6개월 성능:
-33.47%
1년 성능:
-28.96%
1일 변동 폭
$3.2296
$3.7237
1주일 범위
$2.9101
$3.7237
52주 변동 폭
$2.45
$6.97
Envveno Medical Corporation Stock (NVNO) Company Profile
명칭
Envveno Medical Corporation
전화
949-261-2900
주소
70 DOPPLER, IRVINE
NVNO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corporation
|
3.36 | 58.92M | 0 | -24.05M | -17.78M | -2.15 |
|
ABT
Abbott Laboratories
|
113.83 | 197.43B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
361.52 | 137.82B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
90.69 | 133.66B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
80.95 | 103.80B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
73.91 | 43.59B | 6.60B | 4.16B | 490.10M | 6.93 |
Envveno Medical Corporation 주식(NVNO)의 최신 뉴스
Insider Buying: Francis Duhay Acquires Shares of enVVeno Medical Corp - GuruFocus.com
Envveno medical director Duhay Francis buys $249,999 in stock By Investing.com - Investing.com Canada
Envveno medical director Duhay Francis buys $249,999 in stock - Investing.com
Insider Buying: Robert Gray Acquires 3,500 Shares of enVVeno Med - GuruFocus.com
Envveno medical director Robert Gray buys $10,290 in shares - Investing.com
Envveno medical director Robert Gray buys $10,290 in shares By Investing.com - Investing.com Canada
enVVeno Medical Corporation (NASDAQ:NVNO) Director Purchases $10,290.00 in Stock - MarketBeat
enVVeno Medical Corporation (NASDAQ:NVNO) Director Acquires $15,660.00 in Stock - MarketBeat
Insider Buying: Sanjay Shrivastava Acquires Shares in enVVeno Me - GuruFocus.com
Envveno Medical's director Sanjay Shrivastava buys $15,660 in stock - Investing.com
Insider Buying: Matthew Jenusaitis Acquires 9,620 Shares of enVV - GuruFocus.com
Envveno medical director Matthew Jenusaitis buys $24,338 in stock By Investing.com - Investing.com Nigeria
Envveno medical director Matthew Jenusaitis buys $24,338 in stock - Investing.com India
Critical Survey: enVVeno Medical (NASDAQ:NVNO) versus Profound Medical (NASDAQ:PROF) - Defense World
NVNO stock touches 52-week low at $2.5 amid market challenges By Investing.com - Investing.com South Africa
NVNO stock touches 52-week low at $2.5 amid market challenges - Investing.com
Envveno Medical CEO Robert Berman acquires $30,599 in stock By Investing.com - Investing.com Australia
CEO Robert Berman Increases Stake in enVVeno Medical Corp with R - GuruFocus.com
Envveno Medical CEO Robert Berman acquires $30,599 in stock - Investing.com
enVVeno Medical completes final wave of implants in pre-clinical GLP study - TipRanks
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe - AccessWire
enVVeno Medical Completes Key Pre-Clinical Study for Revolutionary Venous Valve, Advances FDA Approval Path - StockTitan
NVNO Stock Touches 52-Week Low at $2.9 Amid Market Challenges - Investing.com
enVVeno launches recap website highlighting VEITH Symposium participation - TipRanks
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website - Kansas City Star
enVVeno Medical Showcases Breakthrough VenoValve Trial Data at VEITH Symposium | NVNO Stock News - StockTitan
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain - MSN
enVVeno Medical (NASDAQ:NVNO) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Reviewing enVVeno Medical (NASDAQ:NVNO) and Cerus (NASDAQ:CERS) - Defense World
PMA application submitted for VenoValve device - Venous News
enVVeno Medical (STU:5HJ) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
enVVeno Medical rises on submission of the venovalve PMA application for FDA approval - MSN
One-year data from the VenoValve US pivotal trial emerge - Venous News
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium - AccessWire
enVVeno Medical's VenoValve Trial Shows 85% Success Rate in Pivotal Study | NVNO Stock News - StockTitan
enVVeno Medical seeks FDA approval for VenoValve - Investing.com India
enVVeno Medical seeks FDA approval for VenoValve By Investing.com - Investing.com Canada
enVVeno Medical submits VenoValve PMA application to FDA - TipRanks
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval - AccessWire
enVVeno Medical Submits Final FDA Module for VenoValve Breakthrough Device | NVNO Stock News - StockTitan
Deep Venous Disease Treatment Devices Market 2024-2031 - openPR
Perceptive Advisors LLC's Strategic Acquisition in enVVeno Medical Corp - GuruFocus.com
enVVeno Medical (FRA:5HJ) Cyclically Adjusted FCF per Share : €0.00 (As of Jun. 2024) - GuruFocus.com
enVVeno Medical expects capital to fund company through several milestones - TipRanks
enVVeno Medical reports Q3 EPS (35c) vs. (45c) last year - TipRanks
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year - AccessWire
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
enVVeno Medical initiates six-month pre-clinical GLP study of enVVe - TipRanks
Envveno Medical Corporation (NVNO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Envveno Medical Corporation 주식 (NVNO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gray Robert | Director |
Dec 31 '24 |
Buy |
2.94 |
3,500 |
10,290 |
11,155 |
| Shrivastava Sanjay | Director |
Dec 24 '24 |
Buy |
2.90 |
5,400 |
15,660 |
9,288 |
| Jenusaitis Matthew | Director |
Dec 19 '24 |
Buy |
2.53 |
9,620 |
24,339 |
16,545 |
| BERMAN ROBERT ANDREW | Chief Executive Officer |
Dec 19 '24 |
Buy |
2.55 |
12,000 |
30,600 |
222,236 |
| Alavi Hamed | Chief Technology Officer |
Mar 13 '24 |
Option Exercise |
3.59 |
8,334 |
29,919 |
8,334 |
| Alavi Hamed | Chief Technology Officer |
Mar 13 '24 |
Sale |
6.22 |
8,334 |
51,837 |
0 |
0.82%
자본화:
|
볼륨(24시간):